Skip to content
Research Article Open access CC BY 4.0

Evaluation of Time in Therapeutic Range of Patients with Non-Valvular Atrial Fibrillation on Oral Anticoagulation with Vitamin K Antagonist in Delta Region

Mohamed Kamel Abdel Aal, Mohamed Bayoumi Nassar, Ehab Elgendy, Seham Fahmy Badr

Cardiology and Angiology: An International Journal · pp. 32–38 · Published 26 Jun 2021

10.9734/ca/2021/v10i330172

Abstract

Background: Non-valvular atrial fibrillation (AF) is the most common cardiac arrhythmia with a prevalence as high as 1.5±2.0% in the general population. This arrhythmia remains one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity in the world. The aim of study was to evaluation of the patients in delta region who have non-valvular AF and on oral anticoagulation with Vitamin K antagonist as regard the time they spend within therapeutic range. Patients and Methods: A total of 100 patients were included in this study for evaluation of the patients in delta region who have non-valvular AF and on oral anticoagulation with Vitamin K antagonist as regard the time they spend within therapeutic range. Results: Our study showed that only 35% achieved the recommended TTR (percent time in therapeutic range) above 60% from studied risk factors, none showed statistical significance. Conclusions: The quality of anticoagulant control was lower that reported in European countries with a significant proportion of patients had TTR below 60%.

Non-Valvular atrial fibrillation oral anticoagulation Vitamin K antagonist delta region

References (22)

  1. 1 Apixaban versus Warfarin in Patients with Atrial Fibrillation [DOI]
  2. 2 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS [DOI]
  3. 3 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS [DOI]
  4. 4 Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial [DOI]
  5. 5 Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review [DOI]
  6. 6 Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation [DOI]
  7. 7 Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States [DOI]
  8. 8 Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care [DOI]
  9. 9 Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial [DOI]
  10. 10 Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies [DOI]
  11. 11 Risk of Falls and Major Bleeds in Patients on Oral Anticoagulation Therapy [DOI]
  12. 12 Outcomes in a Warfarin-Treated Population With Atrial Fibrillation [DOI]
  13. 13 Anticoagulants for atrial fibrillation: Why is the treatment rate so low? [DOI]
  14. 14 Quality of anticoagulation control among patients with atrial fibrillation.
  15. 15 Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study [DOI]
  16. 16 Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement [DOI]
  17. 17 Evaluation of Time in Therapeutic Range (TTR) in Patients with Non-Valvular Atrial Fibrillation Receiving Treatment with Warfarin in Tehran, Iran: A Cross-Sectional Study [DOI]
  18. 18 The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: warfarin -tr [DOI]
  19. 19 Risk of Falls and Major Bleeds in Patients on Oral Anticoagulation Therapy [DOI]
  20. 20 Quality of anticoagulation with warfarin across Kuwait.
  21. 21 Age as a Risk Factor for Stroke in Atrial Fibrillation Patients: Implications for Thromboprophylaxis [DOI]
  22. 22 Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation – real-life data from a survey in Eastern Switzerland [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

54

Page views

0

PDF downloads

8

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.